Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective
Background SARS-CoV-2 is a newly emerged human coronavirus that severely affected human health and the economy. The viral RNA-dependent RNA polymerase (RdRp) is a crucial protein target to stop virus replication. The adenosine derivative, remdesivir, was authorized for emergency use 10 months ago by the United States FDA against COVID-19 despite its doubtful efficacy against SARS-CoV-2. Methods A dozen modifications based on remdesivir are tested against SARS-CoV-2 RdRp using combined molecular docking and dynamics simulation in this work. Results The results reveal a better binding affinity of 11 modifications compared to remdesivir. Compounds 8, 9, 10, and 11 show the best binding affinities against SARS-CoV-2 RdRp conformations gathered during 100 ns of the Molecular Dynamics Simulation (MDS) run (− 8.13 ± 0.45 kcal/mol, − 8.09 ± 0.67 kcal/mol, − 8.09 ± 0.64 kcal/mol, and − 8.07 ± 0.73 kcal/mol, respectively). Conclusions The present study suggests these four compounds as potential SARS-CoV-2 RdRp inhibitors, which need to be validated experimentally. Graphic abstract.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
---|---|
Enthalten in: |
Pharmacological reports - 73(2021), 6 vom: 24. Juni, Seite 1754-1764 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Sonousi, Amr [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
Computational drug design |
Anmerkungen: |
© Maj Institute of Pharmacology Polish Academy of Sciences 2021 |
---|
doi: |
10.1007/s43440-021-00300-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2077469056 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2077469056 | ||
003 | DE-627 | ||
005 | 20230514105517.0 | ||
007 | tu | ||
008 | 221220s2021 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s43440-021-00300-9 |2 doi | |
035 | |a (DE-627)OLC2077469056 | ||
035 | |a (DE-He213)s43440-021-00300-9-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a PHARM |q DE-84 |2 fid | ||
084 | |a 15,3 |2 ssgn | ||
084 | |a 44.40$jPharmazie$jPharmazeutika |2 bkl | ||
100 | 1 | |a Sonousi, Amr |e verfasserin |4 aut | |
245 | 1 | 0 | |a Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © Maj Institute of Pharmacology Polish Academy of Sciences 2021 | ||
520 | |a Background SARS-CoV-2 is a newly emerged human coronavirus that severely affected human health and the economy. The viral RNA-dependent RNA polymerase (RdRp) is a crucial protein target to stop virus replication. The adenosine derivative, remdesivir, was authorized for emergency use 10 months ago by the United States FDA against COVID-19 despite its doubtful efficacy against SARS-CoV-2. Methods A dozen modifications based on remdesivir are tested against SARS-CoV-2 RdRp using combined molecular docking and dynamics simulation in this work. Results The results reveal a better binding affinity of 11 modifications compared to remdesivir. Compounds 8, 9, 10, and 11 show the best binding affinities against SARS-CoV-2 RdRp conformations gathered during 100 ns of the Molecular Dynamics Simulation (MDS) run (− 8.13 ± 0.45 kcal/mol, − 8.09 ± 0.67 kcal/mol, − 8.09 ± 0.64 kcal/mol, and − 8.07 ± 0.73 kcal/mol, respectively). Conclusions The present study suggests these four compounds as potential SARS-CoV-2 RdRp inhibitors, which need to be validated experimentally. Graphic abstract | ||
650 | 4 | |a Remdesivir | |
650 | 4 | |a Medicinal | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a Computational drug design | |
650 | 4 | |a Nucleotide inhibitors | |
650 | 4 | |a RdRp | |
700 | 1 | |a Mahran, Hanan A. |4 aut | |
700 | 1 | |a Ibrahim, Ibrahim M. |4 aut | |
700 | 1 | |a Ibrahim, Mohamed N. |4 aut | |
700 | 1 | |a Elfiky, Abdo A. |0 (orcid)0000-0003-4600-6240 |4 aut | |
700 | 1 | |a Elshemey, Wael M. |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmacological reports |d Springer International Publishing, 2005 |g 73(2021), 6 vom: 24. Juni, Seite 1754-1764 |w (DE-627)485244918 |w (DE-600)2186248-5 |w (DE-576)435514369 |x 1734-1140 |7 nnns |
773 | 1 | 8 | |g volume:73 |g year:2021 |g number:6 |g day:24 |g month:06 |g pages:1754-1764 |
856 | 4 | 1 | |u https://doi.org/10.1007/s43440-021-00300-9 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a SSG-OPC-PHA | ||
936 | b | k | |a 44.40$jPharmazie$jPharmazeutika |q VZ |0 106423304 |0 (DE-625)106423304 |
951 | |a AR | ||
952 | |d 73 |j 2021 |e 6 |b 24 |c 06 |h 1754-1764 |